Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylase complex subunit SAP30 (SAP30) is a core component of the SIN3/HDAC histone deacetylase complex, acting as a scaffold that recruits the complex to specific genomic loci, thereby mediating transcriptional repression through histone deacetylation[1][2][3][4][5][6][7]. SAP30 interacts with key partners such as SIN3A, HDAC1, HDAC2, RbAp46/48, and others, influencing chromatin structure and gene expression. It can bind DNA and is regulated by nuclear phosphoinositides. In human cancers, including clear cell renal cell carcinoma, SAP30 is implicated in tumor proliferation and apoptosis—partly via repression of MT1G and p53 activity—making it a potential therapeutic and prognostic target[4]. No drugs are known to directly target SAP30, but it is essential for the function of HDAC complexes, which are therapeutically targeted in oncology and other diseases.
When part of an HDAC complex, inhibition by HDAC inhibitors leads to increased histone acetylation and de-represssion of gene expression; SAP30 mediates recruitment of HDAC activity to specific gene loci.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone deacetylase complex subunit SAP30 (SAP30).